CLS-logo.png Concept Life Sciences offers a comprehensive service for pre-formulation and formulation development plus GMP sample production for pre-clinical trial materials. We test and release formulations according to development specifications and produce samples under GMP conditions ready for transfer to study teams.

Our formulation team undertake programs such as maximizing the in-vivo exposure of an NCE for toxicity assessing, formulation de-risking programs, solubility enhancement via excipient screening (using our proprietary solubility screen), developing amorphous solid dispersions, particle size reduction via milling to generate suspensions of nano-sized API in a suitable dosing vehicle (nanosuspension).

We have available a wide range of characterization tools in support of formulation development encompassing parenteral, oral, topical and inhalation products.

Full suite of physical and chemical characterization techniques

Additional solid form optimization services such as polymorph screening/salt screening, micronising or blending to prepare samples for further development can be undertaken in house; these services are also supported by a full suite of physical and chemical characterization techniques.

Additional API processing services such as micronising or blending to prepare samples for further development can be undertaken and we carry out such work on site with characterization analysis.


  • Freeze Drier (SCANVAC 110-U PRO)
  • Food Pharma Systems Pilot Mill 2 microniser
  • Heidolph Titramax 1000 shaking heating incubator
  • Homogeniser (IKA T25D)
  • Multi inlet vortex mixer (4 port custom design)
  • Combined impinging jets mixer (custom design)
  • Turbula Blender T2F
  • Spex 8000M-230 Ball mill
  • Fritsch Pulverisette 5 Nano mill with small volume adapter

Pre-formulation / Pre-nomination / Formulation

  • Screens: Salt / Polymorph / Crystallisation / Co-crystal
  • Extensive API characterization, including NMR and single crystal XRD
  • Solubility in aqueous, organic, biorelevant media
  • Absolute solubility
  • pKa, LogP/D outputs, Drug absorption modeling
  • Multi-gram scale-up
  • Enabling formulations, Solubility enhancement, Controlled release
  • Tablets, capsules, liquids, suspensions, pulmonary (pMDI / DPI)


  • Particle size reduction including micronisation and nano-milling (g to kg)
  • Lyophilisation (g to kg)
  • Evaporation (e.g. Rotary Evaporation to 10L)
  • Generation of amorphous material (e.g. HME and spray drying)
  • Powder blending and release for tox trials